Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12294482 | 0.92 | KDM4E (0.36) | CYP17A1KDM4EGSK3BHSD17B10HPGD | |
| SCHEMBL15429606 | 0.89 | KDM4E (0.36) | KDM4EGSK3BHSD17B10LMNAADORA2A | |
| SCHEMBL17323174 | 0.80 | GSK3B (0.31) | KDM4EGSK3B | |
| SCHEMBL2707318 | 0.80 | KDM4E (0.35) | KDM4EHSD17B10HPGDGFERLMNA | |
| SCHEMBL13561501 | 0.78 | KDM4E (0.44) | KDM4EGSK3BHSD17B10HPGDLMNA | |
| SCHEMBL12327996 | 0.78 | LMNA (0.39) | CYP17A1KDM4EHSD17B10HPGDGFER | |
| SCHEMBL10118796 | 0.77 | PSMB5 (0.36) | KDM4EHSD17B10HPGDGFERLMNA | |
| SCHEMBL10118798 | 0.77 | KDM4E (0.36) | KDM4EHSD17B10HPGDGFERLMNA | |
| SCHEMBL10118797 | 0.76 | NPSR1 (0.36) | KDM4EHSD17B10LMNANPSR1CHRNB2 | |
| SCHEMBL15042845 | 0.75 | NPSR1 (0.33) | KDM4EHSD17B10HPGDGFERLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222034-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222034-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP17A1 514/4885KDM4E 1173/4885GSK3B 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.